Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Navidea Biopharmaceuticals Inc (NYSE MKT LLC:NAVB)

0.9062
Delayed Data
As of Feb 12
 +0.0672 / +8.01%
Today’s Change
0.75
Today|||52-Week Range
2.50
-31.86%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$141.1M

Company Description

Navidea Biopharmaceuticals, Inc. develops and commercializes precision diagnostics and radiopharmaceutical agents, which are intended to improve diagnostic accuracy, clinical decision-making and patient care. Its current radiopharmaceutical development programs include Lymphoseek, AZD4694 and RIGScan agents, which are used in treating various tumor cancers. The company's primary focus in to improve surgery outcomes by using market-leading gamma detection devices in combination with radiopharmaceutical agents. The company was founded in 1983 and is headquartered in Dublin, OH.

Contact Information

Navidea Biopharmaceuticals, Inc.
5600 Blazer Parkway
Dublin Ohio 43017-1367
P:(614) 793-7500
Investor Relations:
(617) 532-0624

Employees

Shareholders

Mutual fund holders9.09%
Other institutional27.19%
Individual stakeholders11.04%

Top Executives

Ricardo J. GonzalezPresident, Chief Executive Officer & Director
Brent L. LarsonCFO, Secretary, Treasurer & Executive VP
Frederick O. CopeChief Scientific Officer & Senior Vice President
David ColbornVice President-Clinical Operations
Michael TomblynChief Medical Officer & Senior Vice President